Harvard Bioscience (HBIO) EBT (2010 - 2026)

Harvard Bioscience (HBIO) has reported EBT for 17 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 28.48% year-over-year to -$2.9 million in Q2 2026; TTM through Jun 2026 was -$10.5 million, a 81.49% increase from a year earlier, with the FY2025 full-year figure at -$57.4 million, down 391.95% from the prior year.
• EBT was -$2.9 million for Q2 2026 at Harvard Bioscience, up from -$3.3 million in the prior quarter.
• Over five years, EBT peaked at $3.4 million in Q2 2022 and troughed at -$50.8 million in Q1 2025.
• A 5-year average of -$4.8 million and a median of -$2.6 million in 2025 frame the typical range for EBT.
• The widest YoY moves for EBT: up 641.3% in 2022, down 10522.22% in 2022.
• Over 5 years, EBT stood at -$892000.0 in 2022, then fell by 23.65% to -$1.1 million in 2023, then soared by 153.49% to $590000.0 in 2024, then tumbled by 643.05% to -$3.2 million in 2025, then gained by 9.61% to -$2.9 million in 2026.
• The last three EBT figures came in at -$2.9 million (Q2 2026), -$3.3 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.